PMID- 32447055
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211204
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 415
DP  - 2020 Aug 15
TI  - The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy 
      in a "real world" context: focus on temporal lobe epilepsy.
PG  - 116903
LID - S0022-510X(20)30240-9 [pii]
LID - 10.1016/j.jns.2020.116903 [doi]
AB  - BACKGROUND: Perampanel (PER) is a novel antiepileptic drug approved as an add-on 
      therapy for focal onset seizures with or without generalization and primary 
      generalized tonic-clonic seizures. Aim of this study was to evaluate PER efficacy 
      and tolerability as add-on therapy in patients with drug-resistant focal onset 
      seizures and especially temporal lobe epilepsy (TLE). METHODS: An observational, 
      prospective, multicentre study on adult with drug-resistant focal epilepsy 
      consecutively recruited from six Italian tertiary epilepsy centres. All patients 
      received add-on PER according to indication and clinical judgement. Seizure 
      frequency and adverse events (AEs) were recorded at 6 and 12 months after PER 
      introduction. RESULTS: Study sample comprised 246 patients, 77 of which with TLE. 
      Seventy-five (35.9%) out of 209 and 66 (38.8%) out of 170 patients still taking 
      PER resulted to be responders (i.e. >/=50% of seizure frequency or seizure free) 
      after six and 12 months, respectively. In the TLE group, 39 (57.3%) out of 68 
      subjects on PER after 6 months and 32 (60.4%) out of 53 subjects taking PER after 
      12 months were responders. Overall reported incidence of AEs was 26.1%. In 28 
      cases (11.3%) AEs lead/contributed to PER discontinuation. The most frequently 
      reported AE were dizziness (14/84) and somnolence (14/84). Regarding TLE 
      patients, 25.9% of them experienced at least one AE and discontinuation for AEs 
      occurred in eight (10.4%). CONCLUSIONS: This study confirmed the good efficacy 
      and safety of PER for drug-resistant focal epilepsy in real-life conditions and, 
      above all, for the first time provide its effectiveness in patients with TLE.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Pascarella, Angelo
AU  - Pascarella A
AD  - Institute of Neurology, University "Magna Graecia", Catanzaro, Italy.
FAU - Iannone, Luigi Francesco
AU  - Iannone LF
AD  - Dept of Health Science, School of Medicine, University of Catanzaro, Catanzaro, 
      Italy.
FAU - Di Gennaro, Giancarlo
AU  - Di Gennaro G
AD  - Department of Neurology, Mediterranean Neurological Institute, Pozzilli, Italy.
FAU - D'Aniello, Alfredo
AU  - D'Aniello A
AD  - Department of Neurology, Mediterranean Neurological Institute, Pozzilli, Italy.
FAU - Ferlazzo, Edoardo
AU  - Ferlazzo E
AD  - Institute of Neurology, University "Magna Graecia", Catanzaro, Italy; Regional 
      Epilepsy Centre, Great Metropolitan Hospital, Via Melacrino, Reggio Calabria, 
      Italy.
FAU - Gagliostro, Nazareno
AU  - Gagliostro N
AD  - Dept of Health Science, School of Medicine, University of Catanzaro, Catanzaro, 
      Italy.
FAU - Ursini, Francesco
AU  - Ursini F
AD  - Department of Biomedical Science and Neuromotor Sciences DIBINEM, Bologna, Italy.
FAU - Bonanni, Paolo
AU  - Bonanni P
AD  - Scientific Institute, IRCCS E. Medea, Epilepsy and Clinical Neurophysiology Unit, 
      Conegliano, Treviso, Italy.
FAU - Paciello, Nicola
AU  - Paciello N
AD  - Department of Neurology, San Carlo Regional Hospital, Potenza, Italy.
FAU - Romigi, Andrea
AU  - Romigi A
AD  - Department of Neurology, Mediterranean Neurological Institute, Pozzilli, Italy.
FAU - Aguglia, Umberto
AU  - Aguglia U
AD  - Institute of Neurology, University "Magna Graecia", Catanzaro, Italy; Regional 
      Epilepsy Centre, Great Metropolitan Hospital, Via Melacrino, Reggio Calabria, 
      Italy.
FAU - De Sarro, Giovambattista
AU  - De Sarro G
AD  - Dept of Health Science, School of Medicine, University of Catanzaro, Catanzaro, 
      Italy.
FAU - Russo, Emilio
AU  - Russo E
AD  - Dept of Health Science, School of Medicine, University of Catanzaro, Catanzaro, 
      Italy.
FAU - Gambardella, Antonio
AU  - Gambardella A
AD  - Institute of Neurology, University "Magna Graecia", Catanzaro, Italy.
FAU - Labate, Angelo
AU  - Labate A
AD  - Institute of Neurology, University "Magna Graecia", Catanzaro, Italy. Electronic 
      address: labate@unicz.it.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200515
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Anticonvulsants)
RN  - 0 (Nitriles)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Pyridones)
RN  - H821664NPK (perampanel)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/therapeutic use
MH  - Drug Therapy, Combination
MH  - *Epilepsy, Temporal Lobe/drug therapy
MH  - Humans
MH  - Italy
MH  - Nitriles
MH  - *Pharmaceutical Preparations
MH  - Prospective Studies
MH  - Pyridones
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiepileptic drugs
OT  - Drug-resistant epilepsy
OT  - Focal seizures
OT  - Perampanel
OT  - Temporal lobe epilepsy
EDAT- 2020/05/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/25 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/05/25 06:00 [entrez]
AID - S0022-510X(20)30240-9 [pii]
AID - 10.1016/j.jns.2020.116903 [doi]
PST - ppublish
SO  - J Neurol Sci. 2020 Aug 15;415:116903. doi: 10.1016/j.jns.2020.116903. Epub 2020 
      May 15.